Receptor News and Research

RSS

Gtx, Inc. reports Q2 2009 results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2009. The net loss for the second quarter and six months ended June 30, 2009 was $11.3 million and $22.6 million, respectively, compared with a net loss of $13.2 million and $26.0 million for the same periods in 2008. At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million.

10 Aug 2009

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

6 Aug 2009

Reversible cell-specific drug delivery with aptamer-functionalized liposomes

For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug must also spare healthy cells, and - ideally - its effects will be reversible, to cut short any potentially dangerous side effects.

6 Aug 2009

Success of GERD therapy hinges on medication type and physician bedside manner

Patient satisfaction with their medications and the quality of interactions with their doctor reflect the success of gastroesophageal reflux disease (GERD) therapy, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.

3 Aug 2009

Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo

OSI Pharmaceuticals, Inc. has announced further results from the Phase III SATURN study showing that Tarceva® (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC) when used as single agent, maintenance therapy in patients who did not progress following first-line treatment with platinum-based chemotherapy.

2 Aug 2009

Gene therapy for retinitis pigmentosa

An international team of scientists and clinicians from the United States and Saudi Arabia are working to develop gene therapy for treating a rare, hereditary retinal disease.

31 Jul 2009

Common food additive lecithin may help control blood lipids and reduce disease risk

Scientists at Washington University School of Medicine in St. Louis have identified a substance in the liver that helps process fat and glucose. That substance is a component of the common food additive lecithin, and researchers speculate it may one day be possible to use lecithin products to control blood lipids and reduce risk for diabetes, hypertension or cardiovascular disease using treatments delivered in food rather than medication.

31 Jul 2009

Acute stress improves working memory

Day after day of chronic stress will wear a person down physically and mentally. But new research suggests that the acute stress produced by a brief run-in with a stressful scenario acts on a key brain region controlling emotion and cognition, temporarily improving learning and memory.

28 Jul 2009

Research builds on previous Par-4 study that produced cancer-resistant mouse

Human cells are able to secrete a cancer-killing protein, scientists at the University of Kentucky's Markey Cancer Center have found.

26 Jul 2009

Growth factor enhances heart regeneration, improves heart function without need for cardiac stem cells

Injured heart tissue normally can't regrow, but researchers at Children's Hospital Boston have now laid the groundwork for regenerating heart tissue after a heart attack, in patients with heart failure, or in children with congenital heart defects.

24 Jul 2009

Caspase-8 protein plays an important role in proliferation and invasion of cancer cells

Scientists at Burnham Institute for Medical Research have found that the Caspase-8 protein, long known to play a major role in promoting programmed cell death (apoptosis), helps relay signals that can cause cancer cells to proliferate, migrate and invade surrounding tissues. The study was published in the journal Cancer Research on June 15.

24 Jul 2009

Short stressful events may improve working memory

Experiencing chronic stress day after day can produce wear and tear on the body physically and mentally, and can have a detrimental effect on learning and emotion. However, acute stress -- a short stressful incident -- may enhance learning and memory.

23 Jul 2009

UT Southwestern Medical Center grant aids study of lung cancer in people who never smoked

Researchers at UT Southwestern Medical Center are among an elite group of cancer scientists to share a $2 million grant to find biomarkers for lung cancer that develops in people who have never smoked.

21 Jul 2009

Nanoparticles image breast cancer

Current methods of detecting breast cancer suffer from low sensitivity, limited spatial resolution, or the need to use complicated and expensive radioisotope-based technologies.

21 Jul 2009

Targeted nanoparticles boost arsenic’s anticancer punch

Arsenic trioxide has a long history as a potent human poison, but it also has proven valuable as one of the primary treatment options for acute promyelocytic leukemia. Efforts to use arsenic trioxide to treat other types of cancer are under way, but clinical trials are revealing that the extreme toxicity of this material is likely to limit its utility as a broad-spectrum anticancer agent.

21 Jul 2009

Discovery of new molecular pathway for targeting cancer

A UCLA study has identified a way to turn off a key signaling pathway involved in physiological processes that can also stimulate the development of cancer and other diseases. The findings may lead to new treatments and targeted drugs using this approach.

20 Jul 2009

Gene variants associated with survival advantage in African Americans with HIV

From the start of the HIV epidemic, it appeared that some of the people who were infected with the virus were able to ward off the fatal effects of the disease longer than others.

20 Jul 2009

Nanoparticle Trojan horse for ovarian cancer

In a feat of trickery, Dartmouth Medical School immunologists have devised a Trojan horse to help overcome ovarian cancer, unleashing a surprise killer in the surroundings of a hard-to-treat tumor.

19 Jul 2009

TGF beta blocker prevents epilepsy following traumatic brain injury

Dr. Alon Friedman, a neurosurgeon, professor and researcher at Ben-Gurion University of the Negev, working with researchers from UC Berkeley, California have identified a TGF Beta Blocker that when given to rats prevents epilepsy after brain damage, according to a new study appearing in the July 15 issue of the Journal of Neuroscience.

19 Jul 2009

Discovery of novel receptor in the brain, potential target for Alzheimer's

Barrow Neurological Institute researchers have identified a novel receptor in the brain that is extremely sensitive to beta-amyloid peptide (AB) and may play a key role in early stages of Alzheimer's disease.

17 Jul 2009